Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

Official title

A Pilot Study on the Feasibility and Tolerance of Neoadjuvant Hypofractionated, Stereotactic Body Radiation Therapy Prior to Surgical Resection of Uninodular Hepatocellular Carcinoma.

Overview

Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion". To adequately deal with this phenomenon, the surgeon has to perform either an 'anatomical' liver resection, which remove not only the tumor but also the whole corresponding vascular network, or a 'tumorectomy' with resection margins of at least 2 cm. Unfortunately, these principles cannot always be achieved due to underlying liver cirrhosis that is present in more than 80% of patients. Stereotactic body radiation therapy (SBRT) has been proven to efficiently necrotize or stabilize HCC nodules when surgery is not possible. Our hypothesis is that pre-treatment with SBRT prior to surgical resection of HCC might improve the results through the destruction of possible seeding in the peritumoral environment. Given the novelty of this therapeutic strategy, it is necessary to verify its feasibility and safety, prior to test its efficacy in patients with HCC. The KARCHeR-1 study aims at making sure that preoperative SBRT would not result in important delays or serious adverse events such as to cancel the planned surgical resection, in patients who otherwise could have benefited from it. This issue is commonly called 'drop-out'. Thirty patients are expected to be included in the KARCHeR-1 study, which would be in favor of continuing to evaluate this therapeutic strategy if less than 3 drop-outs occur, and would be immediately discontinued if 3 drop-outs occur. Other outcomes will also been studied, like intraoperative issues, postoperative morbi-mortality, pathological features on the surgical specimen and its correlation with preoperative imaging, and finally, tumor recurrence and survival.

Interventions

• Combination product Surgery with Neoadjuvant stereotactic body radiation therapy
  Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).

Primary outcome measures

• Drop-out rate [Time frame: Five months after the inclusion of the last participating patient]

Secondary outcome measures (10)

• Intraoperative number of packed red blood cells transfused (if any). [Time frame: Postoperative 90 days]
• Toxicity of radiation therapy using the National Cancer Institute CTCAE v.5.0 criteria [Time frame: Postoperative 90 days]
• Duration of surgery. [Time frame: Postoperative 90 days]
• Volume of intraoperative blood loss [Time frame: Postoperative 90 days]
• Quality of life by EORTC QLQ-C30 [Time frame: between before and after stereotactic radiotherapy]
• Intraoperative adverse events [Time frame: Postoperative 90 days]
• Postoperative severe and overall morbidity rate [Time frame: Postoperative 90 days]
• Postoperative mortality rate. [Time frame: Postoperative 90 days]
• Correlation between radiological observations on preoperative imaging and pathological features on surgical specimen (like percentage of tumor necrosis). [Time frame: Postoperative day 30.]
• Actuarial overall survival and disease-free survival. [Time frame: Postoperative 24 months]

Eligibility criteria

Inclusion criteria

• Biopsy-proven hepatocellular carcinoma or EASL/AASLD criteria
• Single nodule, 3 to 8 cm of largest diameter
• Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization

Exclusion criteria

• Performance status > 2
• Severe comorbidity with contraindication for either surgery or radiation therapy
• Decompensated liver cirrhosis (Child-Pugh B or C)
• Neoplastic portal vein thrombosis or extra-hepatic metastases
• Previous anticancer therapy within the last 5 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

France · 1 center

• Hop Claude Huriez Chu Lille — Lille

Identifiers

NCT: NCT04587739 · 2017_03 · 2019-A01441-56

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗